



## NAVANA PHARMACEUTICALS PLC.

Corporate Office : House # 99, Road #04, Block # B,  
Banani, Dhaka-1213

### PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 33<sup>rd</sup> meeting held on January 30, 2024 ended at 4.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Second quarter (Q2) period ended on December 31, 2023 and took the following Price Sensitive Decision:-

#### Comparative Statement on Un-audited Financial Statement for the Second quarter (Q2, FY-2023-2024) period ended on December 31, 2023:

Sl. No	Particulars	01.07.2023-31.12.2023	01.07.2022-31.12.2022	01.10.2023-31.12.2023	01.10.2022-31.12.2022
I	Net Profit After Tax	224,318,207	143,556,922	104,768,117	70,926,497
II	Earnings Per Share (EPS)	2.09	1.57	0.98	0.77
III	Net Operating Cash Flow Per Share (NOCFPS)	0.87	0.87	N/A	N/A
		<b>As on 31.12.2023</b>	<b>As On 30.06.2023</b>		
IV	Net Asset Value (NAV)	4,439,981,797	4,372,445,071	N/A	N/A
V	Net Asset Value Per Share	41.33	40.71	N/A	N/A

#### Notes:

☆ **Reasons of significant deviation in Earning per Share (EPS) between the quarterly periods:**

- EPS: Increase in Sales Revenue and efficient usages of material resulted in increased gross profit as well as increment of Earnings per Share for the reporting period.

☆ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the Second quarter (Q2) period ended on December 31, 2023 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website ([www.navanapharma.com](http://www.navanapharma.com)) of the company.

Dated: January 30, 2024

By order of the Board  
Sd/-  
**Joynul Abedin ACS**  
Company Secretary